Find any stock by ticker or company name
ASE – Real Time Price. Currency in USD
0.28
+0.01 (2.55%)
Market open: Aug 12, 2026, 3:39 PM EDT
0.28
+0.01 (2.23%)
Previous after-hours: Aug 11, 2026, 7:38 PM EDT
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine. It also develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder. The company has license agreements Daewoong Pharmaceutical Co., LTD., and Viatris Inc. The company is based in Irvine, California.
| Name | Position |
|---|---|
| Dr. Chad K. Oh M.D. | Chief Medical Officer |
| Mr. Alex Wilson | Chief Legal & Strategy Officer and Corporate Secretary |
| Mr. John A. Bencich M.B.A. | Chief Financial Officer |
| Mr. Robert Bancroft | President, CEO & Director |
| Ms. Jennifer Sy | Chief Accounting Officer |
| Date | Type | Document |
|---|---|---|
| 2026-08-03 | 8-K | aeon-20260803x8k.htm |
| 2026-07-23 | 8-K | aeon-20260723x8k.htm |
| 2026-07-15 | 8-K | aeon-20260713x8k.htm |
| 2026-07-13 | S-1MEF | tm2615250d9_s1mef.htm |
| 2026-07-09 | S-1/A | tm2615250-6_s1a.htm |
| 2026-07-08 | S-1 | tm2615250-3_s1.htm |
| 2026-06-17 | 8-K | aeon-20260617x8k.htm |
| 2026-05-29 | DRS | filename1.htm |
| 2026-05-14 | 8-K | aeon-20260514x8k.htm |
| 2026-04-29 | DEFA14A | aeon-20231109xdefa14a.htm |